Edition:
India

Nanobiotix SA (NANOB.PA)

NANOB.PA on Paris Stock Exchange

11.59EUR
18 Apr 2019
Change (% chg)

€-0.26 (-2.19%)
Prev Close
€11.85
Open
€11.95
Day's High
€11.95
Day's Low
€11.51
Volume
125,601
Avg. Vol
124,818
52-wk High
€18.87
52-wk Low
€8.30

Latest Key Developments (Source: Significant Developments)

Nanobiotix Announces Results Of Combination NBTXR3, Radiotherapy, And Anti-PD-1 Immunotherapy
Tuesday, 2 Apr 2019 

April 2 (Reuters) - NANOBIOTIX SA ::COMBINATION OF FIRST-IN-CLASS NBTXR3, RADIOTHERAPY, AND ANTI-PD-1 IMMUNOTHERAPY DEMONSTRATE EFFICACY IN TREATING RESISTANT PRE-CLINICAL IN VIVO MODELS OF LUNG CANCER.IN VIVO STUDY DEMONSTRATED NBTXR3 IN COMBINATION WITH PD-1 INHIBITOR ENHANCED ABSCOPAL EFFECT IN BOTH SENSITIVE AND PD-1-INHIBITOR-RESISTANT LUNG CANCER MODELS.IT ALSO DEMONSTRATED NBTXR3 IN COMBINATION WITH PD-1 INHIBITOR SHOWED SIGNIFICANT REDUCTION OF METASTATIC LOAD IN PD-1-INHIBITOR- SENSITIVE LUNG CANCER MODELS.IT ALSO DEMONSTRATED THAT NBTXR3 IN COMBINATION WITH CTLA-4 INHIBITOR ENHANCED AN ABSCOPAL EFFECT IN COLORECTAL CANCER MODELS.  Full Article

Nanobiotix FY Net Loss Grows To 30.3 Million Euros
Friday, 15 Mar 2019 

March 15 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX 2018 ANNUAL RESULTS.CONSOLIDATED CASH AVAILABLE OF €36.2M AT DECEMBER 31, 2018.FY NET LOSS EUR 30.3 MILLION VERSUS LOSS OF EUR 26.1 MILLION YEAR AGO.FY OPERATING LOSS EUR 30.1 MILLION VERSUS LOSS OF EUR 25.3 MILLION YEAR AGO.THIS YEAR NANOBIOTIX EXPECTS TO RECEIVE ITS CE MARK FOR NBTXR3 FOR THE TREATMENT OF SOFT TISSUE SARCOMA,.TOTAL REVENUE IN 2018 AMOUNTED TO €3.5M VERSUS. €3.7M IN 2017.  Full Article

Nanobiotix And MD Anderson Cancer Center Announce Clinical Collaboration On NBTXR3
Monday, 7 Jan 2019 

Jan 7 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX AND MD ANDERSON CANCER CENTER ANNOUNCE A LARGE-SCALE, COMPREHENSIVE CLINICAL COLLABORATION ON NBTXR3.COLLABORATION INCLUDES A $12M TOTAL INVESTMENT FROM NANOBIOTIX.MOST OF TRIALS ARE EXPECTED TO BE LAUNCHED IN 2019.COLLABORATION WILL INITIALLY SUPPORT NINE NEW PHASE I/II CLINICAL TRIALS WITH NANOBIOTIX'S FIRST-IN-CLASS AGENT NBTXR3.PART OF PAYMENT WILL BE MADE AT START OF COLLABORATION.OTHER PARTS WILL BE PAID DURING DEVELOPMENT AND BALANCE IN CASE OF FDA REGISTRATION FOR A TOTAL OF $12M INVESTMENT.  Full Article

Nanobiotix: Positive Phase II/III Results For NBTXR3 In Soft Tissue Sarcoma
Friday, 19 Oct 2018 

Oct 19 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX: POSITIVE PHASE II/III RESULTS FOR NBTXR3 IN SOFT TISSUE SARCOMA PRESENTED AT ESMO.NBTXR3 IS FIRST RADIOTHERAPY ENHANCER TO DEMONSTRATE CLINICALLY MEANINGFUL BENEFIT FOR PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA COMPARED TO RADIOTHERAPY ALONE.NBTXR3 IS FIRST RADIOTHERAPY ENHANCER TO DEMONSTRATE CLINICALLY MEANINGFUL BENEFIT FOR PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA COMPARED TO RADIOTHERAPY ALONE.PRIMARY AND MAIN SECONDARY ENDPOINTS WERE MET.IN SUBGROUP OF PATIENTS HAVING AN ADVANCED DISEASE, 4-TIMES MORE PATIENTS ACHIEVED A PATHOLOGICAL COMPLETE RESPONSE IN NBTXR3 ARM COMPARED TO CONTROL ARM.NBTXR3 SHOWED A GOOD LOCAL TOLERANCE AND NO IMPACT ON SEVERITY OR INCIDENCE OF RADIOTHERAPY-RELATED ADVERSE EVENTS.  Full Article

Nanobiotix H1 Operating Loss 13.0 Million Euros
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - NANOBIOTIX SA ::H1 TOTAL REVENUE EUR 2.1 MILLION VERSUS EUR 1.9 MILLION YEAR AGO.H1 OPERATING LOSS EUR 13.0 MILLION VERSUS LOSS OF EUR 11.8 MILLION YEAR AGO.H1 LOSS EUR 12.6 MILLION VERSUS LOSS OF EUR 12.2 MILLION YEAR AGO.SAYS CASH POSITION AT THE END OF JUNE ENABLES US TO SECURE OUR GROWTH BEYOND 2019.GROUP HAD CASH AND CASH EQUIVALENTS AT JUNE 30, 2018 OF €32.7 M (31 DECEMBER 2017: €47.2M).  Full Article

Nanobiotix Q2 2018 Revenue EUR 73K, Fully In Line With Its Expectations
Thursday, 12 Jul 2018 

July 12 (Reuters) - Nanobiotix SA ::COMPANY GENERATED €73K DURING THE SECOND QUARTER OF 2018, WHICH IS FULLY IN LINE WITH THE COMPANY’S EXPECTATIONS..CURRENTLY, THE COMPANY IS EVALUATING NBTXR3 IN SEVEN CLINICAL TRIALS WITH A FOCUS ON HEAD AND NECK CANCERS AND IMMUNO-ONCOLOGY PROGRAMS.Q2 REVENUE EUR 73,304 VERSUS EUR 58,499 YEAR AGO.  Full Article

Nanobiotix Did Not Generate Any Revenue In Q1
Wednesday, 16 May 2018 

May 16 (Reuters) - NANOBIOTIX SA ::ANNOUNCED ON TUESDAY IT DID NOT GENERATE ANY REVENUE FOR Q1 2018, AS IT HAD EXPECTED.  Full Article

Nanobiotix Partners With The Providence Cancer Institute To Run Immunotherapeutic Preclinical Research In Pancreatic Cancers
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS.COLLABORATION WILL TAKE PLACE OVER COURSE OF ONE YEAR.WILL LAUNCH ITS FIRST CLINICAL TRIAL COMBINING NBTXR3 WITH IMMUNE CHECKPOINT INHIBITORS IN U.S..HAS RECEIVED APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND.  Full Article

Nanobiotix Q3 revenue down at 33.0‍​ million euros
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - NANOBIOTIX SA ::Q3 REVENUE EUR 33.0‍​ MILLION VERSUS EUR 58.6 MILLION YEAR AGO.  Full Article

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology
Monday, 13 Nov 2017 

Nov 13 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX PRESENTED NEW CLINICAL AND PRE-CLINICAL DATA CONFIRMING NBTXR3'S SIGNIFICANT POTENTIAL ROLE IN IMMUNO-ONCOLOGY AT SITC ANNUAL MEETING.‍PATIENTS TREATED WITH NBTXR3 AND RADIOTHERAPY SHOW A MARKED INCREASE OF PD1 AND CD8 INFILTRATION​.‍NBTXR3 ACTIVATED BY RADIOTHERAPY INDUCES SIGNIFICANT ADAPTIVE IMMUNE PATTERN VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH SOFT TISSUE SARCOMA​.‍STRONG DATA TO SUPPORT RATIONAL FOR UPCOMING CLINICAL TRIAL IN COMBINATION WITH CHECK POINT INHIBITORS​.‍PRECLINICAL DATA ON DIFFERENT ANIMAL MODELS CONFIRM BROAD POTENTIAL OF NBTXR3 AS A PRIMER OF IMMUNE RESPONSE​.  Full Article